Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.30 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.30 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about their ongoing projects. They reiterated their commitment to innovation in the biotech space.
Management emphasized their focus on advancing clinical trials.
They highlighted the importance of strategic partnerships for future growth.
IDEAYA Biosciences I reported a loss per share of $1.30, which was not compared to any consensus estimates. Despite this, the stock rose by 2.51%, likely driven by management's positive outlook on their clinical trials and strategic initiatives. Investors may be encouraged by the company's focus on innovation and partnerships.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALGONQUIN PWR & UTIL
Aug 9, 2019